Evgeny M Krupitsky1, Elena A Blokhina. 1. Laboratory of Clinical Psychopharmacology of Addictions, Valdman Institute of Pharmacology, St Petersburg State Pavlov Medical University, St Petersburg, Russia. kru@ek3506.spb.edu
Abstract
PURPOSE OF REVIEW: The major problem with the oral formulation of naltrexone for heroin dependence is poor compliance (adherence). Long-acting sustained release formulations of naltrexone (implantable and injectable) might help to improve compliance and, thus, increase the efficacy of abstinence-oriented treatment of heroin dependence with naltrexone. RECENT FINDINGS: There have been several implantable and injectable formulations of naltrexone developed within the last decade. It was demonstrated that some of them are effective and relatively well tolerated medications for relapse prevention in heroin addicts. However, advantages and disadvantages of these new medications have never been systematically analyzed. SUMMARY: Long-acting sustained release formulations of naltrexone are well tolerated and more effective for relapse prevention in heroin addicts than the oral ones.
PURPOSE OF REVIEW: The major problem with the oral formulation of naltrexone for heroin dependence is poor compliance (adherence). Long-acting sustained release formulations of naltrexone (implantable and injectable) might help to improve compliance and, thus, increase the efficacy of abstinence-oriented treatment of heroin dependence with naltrexone. RECENT FINDINGS: There have been several implantable and injectable formulations of naltrexone developed within the last decade. It was demonstrated that some of them are effective and relatively well tolerated medications for relapse prevention in heroin addicts. However, advantages and disadvantages of these new medications have never been systematically analyzed. SUMMARY: Long-acting sustained release formulations of naltrexone are well tolerated and more effective for relapse prevention in heroin addicts than the oral ones.
Authors: Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody Journal: Am J Drug Alcohol Abuse Date: 2012-03-12 Impact factor: 3.829
Authors: An-Li Wang; Steven B Lowen; Igor Elman; Zhenhao Shi; Victoria P Fairchild; Alexander Bouril; Ruben C Gur; Daniel D Langleben Journal: J Subst Abuse Treat Date: 2017-10-18
Authors: Edward V Nunes; Joshua D Lee; Dominic Sisti; Andrea Segal; Arthur Caplan; Marc Fishman; Genie Bailey; Gregory Brigham; Patricia Novo; Sarah Farkas; John Rotrosen Journal: Contemp Clin Trials Date: 2016-09-28 Impact factor: 2.226